论文部分内容阅读
目的：寻找重症监护病房深部真菌感染患者在治疗期间疗效监测的另外一种新的评估手段方法搜集深圳市福田区人民医院2011-2013年重症监护病房临床诊断、拟诊侵袭性肺部真菌感染合并1,3-β-D葡聚糖升高患者30例，在治疗前、治疗后3天、7天、14天、21天进行血清1,3-β-D葡聚糖检测，进行调查分析。结果30例患者死亡3例，全部患者在抗真菌治疗前1,3-β-D葡聚糖平均值为36.37pg/ml，在抗真菌治疗开始后2例患者1,3-β-D葡聚糖无明显下降，其余25例均呈明显下降，并在1,3-β-D葡聚糖降至一定水平时停药，结果无1例病情反复。结论1,3-β-D葡聚糖可作为深部真菌感染患者抗真菌感染的疗效监测指标。“,”Objective To find a new evaluation method in treatment of ICU patients infected by invasive fungus. Methods 30 cases infected by invasive fungus and accompanied by elevation of (1,3)-β-D Glucan were col ected in ICU of Futian District People’s Hospital from 2011-2013. Serum (1,3)-β-D Glucan were measured on the 0, 3rd, 7th, 14th and 21st day of the treatment, al data were analyzed by statistical software. Results There were three death cases total y. The mean value of serum (1,3)-β-D Glucan before antifungal therapy was 36.37pg/ml, and the mean value appeared significant descending in 25 cases after antifungal therapy started. Antifungal therapy ceased when (1,3)-β-D Glucan level dropped to a certain degree ,and there’s no deterioration case. Conclusion Serum (1,3)-β-D Glucan level can be regarded as an criterion of therapeutic effect in patients infected by invasive fungus.